BioMarin Pharmaceutical (BMRN)
(Real Time Quote from BATS)
$85.43 USD
+1.34 (1.59%)
Updated Jul 22, 2024 03:55 PM ET
After-Market: $85.31 -0.12 (-0.14%) 4:10 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
BioMarin Pharmaceutical Inc. [BMRN]
Reports for Purchase
Showing records 81 - 100 ( 818 total )
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Highlights from HemA KOL Call: Gene Therapy''s Role in the Treatment Landscape
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Ph3 ROCTAVIAN Patient Diagnosed w/ Leukemia Ahead of BLA Resubmission in Sept
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
European Commission Grants CMA to ROCTAVIAN; EU Launch Expected in Q4:22
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q2: Another VOXZOGO Beat & Raise; Focus Remains on ROCTAVIAN Regulatory Path
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
ISTH 2022: Further Insight into ROCTAVIAN Ahead of Potential EU Approval in Q3
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
CHMP Recommends CMA for ROCTAVIAN; Focus Turns to Commercial Opportunity
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
E.N.D.O - Exploring New Drug Opportunities in Endocrinology KOL Call Highlights
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A